Inflammation of blood vessel walls (arteries, veins, or capillaries) resulting from immune-mediated damage to the vascular endothelium, leading to vessel wall thickening, luminal stenosis, aneurysm formation, and downstream tissue ischemia or hemorrhage. Can be primary (idiopathic) or secondary to infectious disease, autoimmune disease, drug reactions, or chronic inflammation. Classified by predominant vessel size affected (large, medium, or small) and underlying immunopathology (ANCA-associated, immune complex-mediated, or cell-mediated).
Imagine the blood vessel network as a city's water pipeline system. In vasculitis, the immune system mistakes the pipe walls themselves for enemy territory and launches an all-out assault. Neutrophils and macrophages are like demolition crews that break through the pipe lining, causing the walls to swell and thicken—like rust and mineral buildup narrowing the diameter. Some pipes become so damaged they bulge outward (aneurysms), like a garden hose with a weak spot ready to burst. Others narrow so much that water flow becomes a trickle, leaving entire neighborhoods (tissues) starved of supply. The inflammation cascades downstream: one blocked pipe means the houses beyond don't get water, just like one inflamed vessel means tissue ischemia. In ANCA-associated vasculitis, it's as if the immune system received faulty blueprints labeling the pipe maintenance crew (neutrophils) as intruders, triggering friendly fire that destroys the very infrastructure it should protect.
Vasculitis pathogenesis involves multiple converging pathways depending on vessel size and immunological trigger:
ANCA-Associated Small Vessel Vasculitis (GPA, MPA, EGPA):
- ANCA autoantibodies (anti-PR3 or anti-MPO) bind to neutrophil surface antigens pre-activated by pro-inflammatory cytokines (TNF-α, IL-1)
- ANCA-neutrophil binding → neutrophil activation → respiratory burst (ROS production) + degranulation (release of proteases, elastase, myeloperoxidase)
- Activated neutrophils adhere to vascular endothelium via selectins (CD62L) and integrins
- NETosis occurs: neutrophils expel chromatin nets (NETs) containing MPO and PR3, creating antigenic scaffold on vessel wall
- Endothelial injury → expression of adhesion molecules (VCAM-1) → recruitment of monocytes and T cells
- Macrophages infiltrate vessel wall → release IL-6, TNF-α, IL-1β → amplification loop
- Cytokines activate NF-κB pathway in endothelial cells → upregulation of pro-inflammatory genes
- Vessel wall necrosis → fibrinoid necrosis → luminal thrombosis or hemorrhage
Immune Complex-Mediated (Henoch-Schönlein Purpura, Cryoglobulinemia):
- Antigen-antibody complexes (often IgA-based) deposit in small vessel walls
- Complement activation (C1q → C5a, C5b) → Membrane Attack Complex formation
- C5a acts as chemokine → neutrophil recruitment
- Fc receptor engagement on neutrophils → phagocytosis attempt → frustrated phagocytosis → degranulation and ROS release
- Endothelial damage and inflammation
Large Vessel (Giant Cell Arteritis, Takayasu):
- T-cell mediated: dendritic cells in vessel adventitia present unknown antigen to CD4+ T cells
- Th1 and Th17 differentiation → IFN-γ and IL-17 production
- IFN-γ → macrophage activation → formation of granulomas with multinucleated giant cells
- IL-17 → recruitment of neutrophils and amplification
- Macrophage-derived VEGF and metalloproteinases (Matrix metalloproteinases (MMPs)) → intimal hyperplasia and vessel remodeling
- Vessel wall thickening → luminal stenosis → ischemic symptoms (jaw claudication, vision loss)
Shared Terminal Pathways:
graph TD
A["Initial Trigger: Infection/Autoantigen/Immune Complex"] --> B[Endothelial Activation]
B --> C["Neutrophil Priming by TNF-α/IL-1"]
C --> D[ANCA Binding to Neutrophils]
D --> E[Neutrophil Activation]
E --> F["Degranulation + ROS Release"]
E --> G[NETosis]
F --> H[Endothelial Injury]
G --> H
H --> I[Expression of VCAM-1/E-selectin]
I --> J[Monocyte/T-cell Recruitment]
J --> K[Macrophage Infiltration]
K --> L["Cytokine Storm: IL-6/TNF-α/IL-1β"]
L --> M["NF-κB Activation"]
M --> N[Amplification Loop]
N --> O[Vessel Wall Necrosis]
O --> P[Stenosis/Aneurysm/Thrombosis]
P --> Q[Tissue Ischemia/Hemorrhage]
Vasculitis represents a critical diagnostic and therapeutic challenge in cPNI practice, as it sits at the nexus of immune dysregulation, chronic inflammation, and vascular pathology. Recognition is urgent: untreated giant cell arteritis carries a 15-20% risk of permanent sight loss within weeks, and systemic vasculitis can rapidly progress to multi-organ failure (renal, neurologic, cardiac).
cPNI Integration:
- Selfish Immune System: Vasculitis exemplifies immune hypervigilance gone awry—the system attacking infrastructure rather than pathogens. Chronic antigen exposure (infections like Hepatitis B, Streptococcus, Epstein-Barr Virus) or persistent Low-grade inflammation may prime autoreactive cells
- Evolutionary Mismatch: Modern triggers include novel antigens (pharmaceuticals, environmental toxins), chronic stress-induced cortisol resistance, and gut barrier dysfunction allowing bacterial translocation and molecular mimicry
- Metamodel 5 (Intervention): Acute management requires conventional immunosuppression (corticosteroids, rituximab, cyclophosphamide), but cPNI addresses root dysregulation—restoring immune tolerance, resolving inflammation via Specialized pro-resolving mediators (SPMs), and repairing barrier function
Clinical Thresholds & Biomarkers:
- ESR typically >50 mm/hr (often >100 in GPA)
- CRP >10 mg/L
- ANCA titers: PR3-ANCA (c-ANCA) >20 units (GPA), MPO-ANCA (p-ANCA) >20 units (MPA)
- IL-6 >10 pg/mL correlates with disease activity
- Urine protein >300 mg/24hr suggests renal involvement
- Temporal artery biopsy: skip lesions with giant cells and intimal thickening (GPA)
Differential Diagnosis:
Must rule out infections (bacterial endocarditis, tuberculosis, HIV), malignancies (paraneoplastic), and drug-induced vasculitis (cocaine, levamisole, propylthiouracil)
cPNI Intervention Considerations:
- Gut-Immune Axis: Address intestinal permeability (Zonulin <2.5 ng/mL target) to reduce endotoxemia and molecular mimicry risk
- Resolution Pharmacology: Post-acute phase, support endogenous Resolvins (RvD1, RvE1) via Omega-3 (EPA 2-4g/day, DHA 1-2g/day)
- Metabolic Optimization: Insulin resistance and Metabolic syndrome amplify vascular inflammation—restore metabolic flexibility
- Stress Axis: Chronic stress → cortisol resistance → unopposed TNF-α and IL-6. Vagal tone restoration (Vagus nerve stimulation, breathing exercises) activates cholinergic anti-inflammatory pathway
- Microbiome: Dysbiosis (low Akkermansia-muciniphila, high Enterobacteriaceae) correlates with autoimmune flares—restore diversity
- Toxin Burden: Screen for heavy metals (cadmium, lead), pesticides, and persistent organic pollutants that trigger oxidative stress and endothelial injury
Patient Phenotypes:
- Giant cell arteritis: typically >50 years, headache, jaw claudication, vision changes, scalp tenderness
- ANCA-associated: sinusitis, pulmonary infiltrates, hematuria (glomerulonephritis), neuropathy
- Kawasaki (children): fever >5 days, rash, conjunctivitis, coronary artery aneurysms
- Classified by predominant vessel size: large (aorta, major branches), medium (visceral arteries), small (capillaries, venules, arterioles)
- ANCA-associated vasculitis (AAV) triad: Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA), Eosinophilic Granulomatosis with Polyangiitis (EGPA)
- Giant cell arteritis incidence: 15-25 per 100,000 in those >50 years; ESR often >100 mm/hr
- Temporal artery biopsy shows "skip lesions"—must sample ≥2 cm to avoid false negatives
- PR3-ANCA (c-ANCA) sensitivity for GPA: 65-90%; MPO-ANCA (p-ANCA) for MPA: 50-80%
- Renal involvement in AAV occurs in 80% of MPA, 70% of GPA (rapidly progressive glomerulonephritis)
- Untreated GPA mortality: 90% within 2 years; with treatment: 75-90% remission
- Triggers include infections (Hepatitis B/C, Streptococcus pyogenes, Staphylococcus aureus), drugs (hydralazine, propylthiouracil, cocaine), and autoimmune overlap (Systemic lupus erythematosus, Rheumatoid arthritis)
- Henoch-Schönlein purpura: IgA immune complex deposition, often post-streptococcal, presents with palpable purpura and arthritis
- Cryoglobulinemic vasculitis: associated with Hepatitis C in 80-90% of cases; manifests as purpura, weakness, arthralgia
- Autoimmunity — ANCA-associated and giant cell arteritis are primary autoimmune processes with loss of self-tolerance to vascular antigens
- Low-grade inflammation — chronic systemic inflammation (elevated CRP, IL-6) predisposes to endothelial activation and vasculitis susceptibility
- Endothelial dysfunction — vasculitis both causes (via direct immune attack) and results from (via oxidative stress, reduced Nitric Oxide) endothelial injury
- Cytokines — TNF-α, IL-1β, Interleukin-6 are master orchestrators of vascular inflammation, driving recruitment and activation cascades
- Infection — molecular mimicry between microbial antigens and vascular proteins can trigger autoimmune vasculitis (e.g., Streptococcus and Kawasaki disease)
- Neutrophil — primary effector cell in ANCA-associated vasculitis; undergoes respiratory burst, degranulation, and NETosis
- Antibodies — ANCA (anti-PR3, anti-MPO), cryoglobulins, and immune complexes mediate endothelial damage
- NF-κB — transcription factor activated in endothelial cells by cytokines, driving expression of adhesion molecules and pro-inflammatory genes
- Complement — C5a generation recruits neutrophils; Membrane Attack Complex (C5b-9) directly damages vessel walls in immune complex vasculitis
- Gut barrier — increased intestinal permeability allows bacterial translocation, triggering systemic inflammation and potential molecular mimicry
- Chronic inflammation — persistent inflammatory state exhausts resolution mechanisms, leaving vessels vulnerable to immune attack
- Cortisol resistance — impaired glucocorticoid signaling allows unopposed TNF-α and IL-6, amplifying vascular inflammation
- Oxidative Stress — ROS from activated neutrophils and mitochondrial dysfunction damage endothelium, perpetuating inflammation
- Matrix metalloproteinases (MMPs) — MMP-2, MMP-9 degrade vascular basement membrane, facilitating immune cell infiltration and aneurysm formation
- Acute phase response — hepatic release of CRP, Ferritin, Serum amyloid A in response to IL-6 elevation; ESR >100 mm/hr common
- Molecular Mimicry — microbial antigens (e.g., streptococcal M protein) share epitopes with vascular proteins, triggering cross-reactive immune attack
- Specialized pro-resolving mediators (SPMs) — RvD1, RvE1, MaR1 deficiency impairs resolution of vascular inflammation, prolonging disease
- Metabolic syndrome — insulin resistance, visceral adiposity, and dyslipidemia amplify endothelial dysfunction and inflammatory cytokine production
- Microbiome — dysbiosis (low Faecalibacterium prausnitzii, Akkermansia-muciniphila) correlates with autoimmune flares and reduced Treg populations
- Vagus nerve — vagal tone activation via cholinergic anti-inflammatory pathway (α7nAChR on macrophages) suppresses TNF-α release and may modulate vasculitis severity
(no module references provided in original note)